As reported on Stock Titan, the European Commission has approved Enhertu® (trastuzumab deruxtecan) as a treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumors who…
As reported on Business Wire, Delcath Systems has announced the enrollment and dosing of the first patient in its global Phase 2 DELUMA clinical trial, marking a significant step in…
Editor's Note: Patient Worthy is honored to share this article from our friend Abigail Johnston, originally published on her blog No Half Measures. To see the article in its original…
As reported in BioPharmaDive, the U.S. Food and Drug Administration (FDA) has postponed its decision on camizestrant, an experimental oral therapy for breast cancer being developed by AstraZeneca, following a…
Editor's Note: This piece, originally written by Kayla DeSonier, was shared with us by our friends at Elephants & Tea. To see the article in its original format, please click…
Editor's Note: Patient Worthy is honored to share this piece from our friends at Elephants & Tea, originally written by Katie Newbaum. To see the article in its original format,…
I’ve always been an overachiever – someone who puts their mind to something and delivers more than was expected, someone who strives for greatness. I never wanted to be an…
Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to prevent recurrence in early-stage breast…
As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care. Data presented at the recent…
As covered on PharmaBiz, Roche has reported topline results from the phase III persevERA Breast Cancer study, which evaluated the oral selective oestrogen receptor degrader (SERD) giredestrant in combination with…
Daiichi Sankyo has taken a significant step forward in expanding treatment options for early-stage breast cancer patients by submitting a supplemental New Drug Application (sNDA) to Japan's Ministry of Health,…
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has accepted and granted Priority Review to AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab…
Editor's Note: Patient Worthy is pleased to bring you this article, originally shared with us by our friend Julie Lanford, The Cancer Dietitian. To see the article in its original…
The landscape of advanced breast cancer treatment is shifting. Genentech's filing acceptance of giredestrant, an experimental oral medication, represents a pivotal moment for thousands of women grappling with a particularly…
Editor's Note: This article was shared with Patient Worthy by our friends at Elephants & Tea. It was originally written by Jenny Gomez, a breast cancer survivor. To see the…
As reported on Science Daily, a breast cancer vaccine tested more than 20 years ago is drawing renewed scientific interest after researchers discovered that every participant in the original trial…
A New Approach to a Persistent Problem Celcuity has reached a critical inflection point in its pursuit of a novel breast cancer treatment. The FDA's acceptance of gedatolisib's New Drug…
A radically new type of optical sensor can identify individual cancer-related proteins in blood, a capability that could revolutionize how early-stage breast cancer is diagnosed and treated. according to Nanowerk.com,…
As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach of annual mammograms. The research,…
A groundbreaking study from Massachusetts General Hospital reveals that artificial intelligence is catching breast cancers that skilled radiologists initially overlook. As reported by Business Wire, Hologic's Genius AI Detection solution…
As reported on BioPharmaDive, the U.S. Food and Drug Administration (FDA) has granted early approval for a new frontline treatment option for HER2-positive metastatic breast cancer. The regimen combines AstraZeneca…
Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive breast cancer. As reported by…
Editor's Note: We're honored to share this patient story-share by Jess Ippolito, originally published by our friends at Stork Genetics. To see the article in its original format, please click…
Women living in areas of the United States with poor air quality, particularly neighborhoods with high motor vehicle emissions, face a greater risk of developing breast cancer, according to a…
A new expert consensus calls for a fundamental shift in how hormone replacement therapy (HRT) is offered to breast cancer survivors suffering severe menopausal symptoms. Published in Menopause on 30…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
